

Propanc Biopharma, Inc.

15:54 15 May 2019


Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Proactive Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board. The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula. Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent. "We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."

Price: 0.003

Market Cap: \$141.26 k

1 Year Share Price Graph



Share Information

Code: PPCB

Listing: OTCQB

52 week	High	Low
	3.05	0.002

Sector: Pharma & Biotech

Website: www.propanc.com

Company Synopsis:

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. Together with our scientific and oncology consultants, we have developed a novel therapeutic approach based on 100 years of the scientific study of enzyme use.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.